Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PPM1A | P35813 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908259 | 0.83 | NR3C1 (0.39) | NPSR1NR3C1 | |
| SCHEMBL18908256 | 0.81 | NPSR1 (0.40) | NPSR1FAAHTAS1R3TAS1R1TSHR | |
| SCHEMBL19292776 | 0.80 | KDM4E (0.41) | KDM4E | |
| SCHEMBL18908288 | 0.75 | KCNH2 (0.32) | NPSR1FAAHMEN1KMT2AKCNH2 | |
| SCHEMBL18908266 | 0.75 | KCNH2 (0.32) | NPSR1FAAHMEN1KMT2AKCNH2 | |
| SCHEMBL20032417 | 0.73 | KDM4E (0.44) | ADRA2AADRA1AKDM4E | |
| SCHEMBL26394016 | 0.71 | KDM4E (0.43) | KDM4ETSHR | |
| SCHEMBL11457685 | 0.70 | HDAC3 (0.42) | ADRA2AADRA1A | |
| SCHEMBL16737884 | 0.70 | HTR2A (0.40) | NPSR1ADRA2AADRA1AKDM4E | |
| SCHEMBL21816552 | 0.70 | ADRA1A (0.50) | ADRA2AADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | NPSR1 4556/4885FAAH 1025/4885ADRA2A 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.